Live Earnings Conference Call: Ascendis Pharma A/S will host a live Q1 2026 earnings call on May 7, 2026 at 8:00AM ET. NASDAQ:ASND Ascendis Pharma A/S Q1 2026 Earnings Report $235.90 +10.62 (+4.71%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$235.38 -0.52 (-0.22%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Live Call not available Upcoming EventEarnings Conference CallAscendis Pharma A/S Q1 202600:00 / 00:00Live Transcript Follow Audio Ascendis Pharma A/S EPS ResultsActual EPSN/AConsensus EPS $0.21Beat/MissN/AOne Year Ago EPSN/AAscendis Pharma A/S Revenue ResultsActual RevenueN/AExpected Revenue$361.87 millionBeat/MissN/AYoY Revenue GrowthN/AAscendis Pharma A/S Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Ascendis Pharma A/S Earnings HeadlinesNew 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 YearsMay 6 at 4:01 PM | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Given Average Rating of "Moderate Buy" by BrokeragesMay 4 at 6:03 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026April 30, 2026 | globenewswire.comAscendis Pharma slides as investors digest share-structure switch and convertible-note redemptionApril 22, 2026 | quiverquant.comQWe Might See A Profit From Ascendis Pharma A/S (NASDAQ:ASND) SoonApril 21, 2026 | finance.yahoo.comSee More Ascendis Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email. Email Address About Ascendis Pharma A/SAscendis Pharma A/S (NASDAQ:ASND) is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia. The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S. Food and Drug Administration for the treatment of pediatric growth hormone deficiency. By transiently conjugating active hormone to a carrier molecule, the TransCon platform allows controlled release of the therapeutic agent over time, reducing injection frequency and helping to maintain more consistent drug exposure. Beyond growth hormone deficiency, Ascendis Pharma is advancing a pipeline of product candidates aimed at other rare endocrine disorders. TransCon parathyroid hormone (PTH) is in clinical development for hypoparathyroidism and has demonstrated positive proof‐of‐concept data. The company is also investigating TransCon CNP for the treatment of achondroplasia, a form of dwarfism, and pursuing additional indications in both endocrine and broader metabolic diseases. Ascendis Pharma’s management team brings together experienced professionals in drug development, regulatory affairs and commercial strategy. The company continues to expand its global footprint through strategic collaborations and partnerships, with the goal of delivering transformative therapies to patients with underserved conditions.View Ascendis Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageDigitalOcean’s AI Surge: How Far Can This Rally Go?Years in the Making, AMD’s Upside Movement Has Just BegunCapital One’s Big Bet Faces Rising Credit RiskWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootHow Williams Companies Is Cashing in on the AI Power Boom Upcoming Earnings Brookfield Asset Management (5/8/2026)Enbridge (5/8/2026)Toyota Motor (5/8/2026)Ubiquiti (5/8/2026)Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
